In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Acorn Saga Continues

Executive Summary

Acorn Cardiovascular and Paracor Medical are frequently compared with one another because they are taking similar approaches to treating heart failure. Acorn has gone through a series of setbacks that have slowed its product development, but it's hoping that this third time is the charm. The company reached agreement with the FDA to embark on a 50-patient clinical trial that Acorn hopes leads to agency clearance of its CorCap device. (This is a sidebar to the article, "Paracor: Can a Mechanical Device Treat Heart Failure?")

You may also be interested in...



BioVentrix: Reshaping Heart Failure

BioVentrix Inc. is developing a unique, minimally invasive approach to reshaping the heart’s scarred and enlarged left ventricle aimed at patients who develop ischemic heart failure following a heart attack. The company has made considerable headway with its technology, which offers an interesting balance between a catheter-based and surgical-based procedure; however, CEO Kenneth Miller, well aware of the pitfalls that have plagued earlier companies in this field, is taking a cautious approach to the US market.

Acorn Cardiovascular: The Virtue of Patience

The whole area of congestive heart failure (CHF) is hot right now, particularly for medical device firms who can offer an alternative to drug therapies, which seem to have hit a wall in advancing treatment options. But Acorn Cardiovasculaar, whose device represents a surgery-based approach to reducing the size of enlarged hearts, faces a crowded device field: not only are left ventricular assist device (LVAD) manufacturers seeking to expand beyond their historic bridge-to-transplant niche, but cardiac rhythm management companies are aggressively promoting their new cardiac resynchronization therapy. Adding to Acorn's challenge: the company has had to extend its commercialization timelines as enrollment in its clinical trial took longer than company officials thought it would and it has spent considerable time building the clinical rationale for its approach. As it prepares to launch its device in the next year or so, Acorn is counting on one edge over other CHF device companies: the growing enthusiasm of surgeons for new procedures, as interventional cardiology takes over more and more of their traditional CABGs.

Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.

Topics

UsernamePublicRestriction

Register

IV002873

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel